ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FUM Futura Medical Plc

38.35
0.10 (0.26%)
07 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.10 0.26% 38.35 38.25 38.35 38.35 38.35 38.35 114,425 16:35:18
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 3.1M -6.51M -0.0217 -17.67 115.32M
Futura Medical Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 38.25p. Over the last year, Futura Medical shares have traded in a share price range of 24.10p to 67.00p.

Futura Medical currently has 300,712,293 shares in issue. The market capitalisation of Futura Medical is £115.32 million. Futura Medical has a price to earnings ratio (PE ratio) of -17.67.

Futura Medical Share Discussion Threads

Showing 20926 to 20942 of 21600 messages
Chat Pages: Latest  840  839  838  837  836  835  834  833  832  831  830  829  Older
DateSubjectAuthorDiscuss
21/2/2024
11:59
Like everyone else I have left an anonymous review and do not plan to divulge that level of personal data on the quality of the experience - you will have to simply infer from my postings - sorry. But I am not really a client as I am healthy in that respect but was wanting to understand the physiological effects etc.

dyor and no advice etc

takeiteasy
21/2/2024
11:50
Eroxon Amazon sales 4000+ in the past monthErexOn Amazon sales 200+ in the past month:- )
broomrigg
21/2/2024
11:24
Erexon: 328 out of 420 (78%) reviewers recommend this product

Eroxon: 336 out of 449 (75%) reviewers don't recommend this product

glavey
21/2/2024
10:48
It's going to be available on NHS prescription from the 1st of March, yet you feel the need to do your own non-randomised clinical trial ?
wheeze
21/2/2024
10:44
Have any investors on this board tried the product?

What was your experience with it?

Do you find that cutting out tea and using coffee instead more effective?

Is horny goat weed more effective than Eroxon in your experience?

martywidget
21/2/2024
08:18
If I was an MM here I would do what they are doing and move down the bid for stop losses - continual surprise how many this picks up each time given the news...hopefully they will happy to stop at 39p and not 35p this time :)

dyor etc

takeiteasy
21/2/2024
06:25
Well done takeiteasy, he hates being silenced.

MDI (aka LBO) is a bitter ex shareholder who lost all his money by selling his FUM shares sub 10p in 2018. He bought high and sold at the all-time low. It's as simple as that.

:- )

broomrigg
20/2/2024
21:27
Petroc, I do not mind someone saying they don;t like the company , the management, the products, the history and whether they are short or not I do not really care either.

What is being done here is to repost mindlessly partial extracts from a scenario that paints an entirely misleading picture of the status quo.

Simply refusing to acknowledge the 60% test outcome when this is fact and restating that this is still a placebo product under the new guise (it was under the old but not new) that needs a double blind trial.

It may mean that you can avoid rules of deliberately misleading as you fall back on "I'm only cut and pasting what's in the public domain' and "I'm not expressing an opinion am I" BS, but this person has done this to an extreme that defies sanity.

He clearly has taken legal advice and so no one can stop him...anyway I will never see his comments again so am delighted to not read the same thing all day every day...

takeiteasy
20/2/2024
18:32
Absolutely spot on there petroc, he is not a shorter or part of some kind of cartel. He's simply a bitter broke nutjob. Deranged. Demented. For a more balanced, honest, uninterrupted discussion LSE is very good.
broomrigg
20/2/2024
16:32
I have managed the position size here - so am very chilled really.

It is a much bigger industry thing - we are hopefully likely to massively disrupt a cosy cartel of interests in the ED industry who are making large profits year after year and will of course compete hard not to lose that business to a new rival.

I did filter this chap a while back and relented (in error) and will not do so again :)

I get your point over the shorters - it seems to me just brainless to keep picking on a share like this one after our recent news. But their money and their choice.

dyor and no advice implied...

takeiteasy
20/2/2024
16:23
Takeiteasy, Take it easy mate - don't let the shorters get you down. You will find blatant deramping of many stocks by punters following the likes of Tommy Williefroth - there is often a wall of money thrown at driving a share down. Plenty of bulletin board trolls posting drivel just to put investors off. My own philosophy is:Do your own research Make your own choices Don't let the trolls get you down Take it easy
wheeze
20/2/2024
15:25
I think I have been on ADVFN for many many years and have never ever come across a board like this one - perhaps I typically keep away from AIM stocks and all the smaller company boards are like this - who knows...it is a great shame that the moderators are so limp in their approach and need to build a stiffer backbone..infuse themselves in Eroxon more like...
takeiteasy
20/2/2024
15:19
‘There was a double blind placebo trial’

Yes it was a Phase 3 drug trial set up and designed to study a completely different GTN gel. It was not a trial set up and designed to study the placebo Eroxon gel. The results of that failed phase 3 GTN gel drug study do not clinically prove that Eroxon which was the placebo gel in that study is not just a placebo gel.



The company that makes MED3000 (Eroxon) also made a different compound called MED2005, a nitroglycerine-containing cream. Two trials have been completed, but only one was published. In the published trial, the results showed that the results for the active drug were only marginally better than a placebo, with about 37% of placebo recipients being satisfied with their experience versus 48% in those who received the active drug.

This means that about one man out of nine who used the active drug found it more helpful than a placebo. It also means that most people who were satisfied with the results were having a placebo response

mdi
20/2/2024
15:18
That's probably him loading up long last trade with 50k shares on the shake out...
takeiteasy
20/2/2024
15:12
Don't worry he makes no difference to the share price or the worldwide rollout of Eroxon.
broomrigg
20/2/2024
15:11
Also a CE Mark for a low class medical device does not mean efficacy is proven either.



Eroxon Is Not a Medication?

No. Because it lacks an active ingredient, the EU granted MED3000 a CE mark which classifies it as a medical device not a medication. Thats important because in European markets, medical devices dont have to show any sort of improvement in symptoms; they just have to meet specific safety standards.

In other words, the CE mark proves only that Eroxon is safe, not that it works.



Does it work?

MED3000 was recently granted a CE mark as an approved medical device in the EU. Does this mean it works? No. Unlike drugs, medical devices don't need to be proven efficacious to be sold; they only need to show conformity with safety regulations, which the CE mark indicates.

So how effective is MED3000 really?

The first thing to note is that MED3000 has never been shown to be more effective than any control treatment - because it was the control treatment.

When Futura describe the efficacy of MED3000, they are talking about improvement seen over the course of the treatment period (which was 1 month in the first trial, 3 months in the second), known as 'change vs. baseline'.

Large improvements vs. baseline are common in the placebo groups in clinical trials of a wide range of conditions. This improvement is sometimes attributed to the 'placebo effect',

mdi
20/2/2024
15:10
MDI - filtered.

There was a double blind placebo trial - it met the end point. Yes, you may drive the price back down to 35p with all this nonsense - but as I said before you have lost the argument.

takeiteasy
Chat Pages: Latest  840  839  838  837  836  835  834  833  832  831  830  829  Older

Your Recent History